Kornimate/medical-research-clean huggingface dataset:
glioma supra marginal incision trial

Conditions: High Grade Glioma

Summary: g-sumit is a pilot, phase ii,randomized controlled trial to evaluate the feasibility of performing a large-scale trial in patients undergoing surgery for first-time diagnosis of high grade glioma (hgg) in a surgically favorable anatomical location to answer the following: does extending the margin of resection 1 cm beyond visible enhanced volume on mri result in (a) an increase in overall survival? (b) result in a similar rate of "clinically-significant" neurological worsening during 30 days post surgery and quality of life at 6 and 12 months?

this pilot, multi-centre, pragmatic randomized controlled trial is planned to simulate all aspects of a larger definitive trial comparing conventional versus supramarginal tumor resection at the time of the first surgical resection of hgg in appropriately selected patients. this pilot will help determine the ability to meet pre-specified criteria in identification, recruitment, and patient allocation, allow for refinement of eligibility criteria for optimal recruitment, confirm safety of procedure and ability to retain participants for the duration of the trial. preliminary efficacy data will inform sample size calculations and estimation of resources required for the envisioned larger definitive trial.

Eligibility criteria:
inclusion criteria: 1. radiographic evidence of a gad-enhancing intra-axial tumor consistent with hgg; 2. age ≥18 ≤ 85 years; 3. karnofsky performance score ≥ 60; 4. location of tumor in a safe anatomical location and 5. patient or substitute decision maker (sdm) able to understand and consent to study participation. exclusion criteria: 1. multi-focal tumor, gliomatosis cerebri (≥3 lobes of the brain affected), tumors crossing the midline, or leptomeningeal enhancement; 2. previous craniotomy for tumor excision (stereotactic biopsy is permitted); 3. known metastatic cancer; 4. uncorrectable coagulopathy; 5. unable to obtain gad-enhanced brain mri.

Keywords: supramarginal resection standard total resection surgery brain tumor hgg
theophylline for depression study

Conditions: Depression

Summary: depression is very common and poses a huge disease burden. about 20% of the us population suffers from depression at least once in their lifetime. inflammations that are hidden inside our body as a result of aging, obesity, chronic diseases, or certain treatments (e.g., interferon for hepatitis c) appear to cause depressive symptoms and even clinical depression. individuals with such inflammations are more likely to suffer from depression and are less likely to respond to currently available antidepressant medications. this study will test theophylline, a medication currently used for asthma treatment, as a new way to mitigate depressive symptoms in response to such inflammations. this study begins with a 90-minute screening session to determine whether participants are eligible to join the main study. those who meet the eligibility criteria will then join the main study, which will consist of taking theophylline or methylcellulose (i.e., oral placebo) for 2 weeks at home and an 8-hour session at the ucla medical center. approximately 20 healthy adults will be recruited for participation in the study. during the course of the study, participants will take theophylline or methylcellulose for 2 weeks at home and then will be injected either lipopolysaccharide (lps) or saline (i.e., intravenous placebo) at the ucla medical center. lps is a bacterial substance that can initiate chemical reactions that are similar to those seen in individuals with mild sickness symptoms, such as a slight increase in body temperature, muscle aches, or tiredness. it is a safe way of investigating the body's response to inflammation and how these changes may alter cognitive, emotional, or neural function. it has been given thousands of times to healthy volunteers - both younger and older adults - without any serious side effects.


Eligibility criteria:
inclusion criteria: * in good general health (as evaluated during the phone and in-person screening sessions) * aged 18-65 years * if female, using adequate birth control exclusion criteria: * history of hypersensitivity to xanthine derivatives (a contraindication to theophylline treatment) * pregnant or planning to become pregnant in the next 6 months * current breastfeeding * chronic diseases such as cardiovascular disease, hepatic impairment, peptic ulcer disease, and seizure disorders * current use of prescription medications such as steroids, non-steroid anti-inflammatory drugs, immune modifying drugs, opioid analgesics, and psychotropics * axis i psychiatric disorders including current major depressive disorder * current depressive symptoms assessed by the patient health questionnaire (phq-9 ≥ 5) * heavy smoking (1 pack or more per day) * excessive caffeine use (\>600 mg/day) * body-mass index \> 35 due to the effects of obesity on cytokine activity * evidence of recreational drug use from urine test * evidence of pregnancy from urine test * evidence of clinically significant rhythm abnormality on a resting electrocardiogram (ecg) * clinically significant abnormalities on screening laboratory tests
cognitive outcomes and wellness in survivors of critical illness

Conditions: Critical Illness

Summary: as survival rates from critical illness improve, strategies to return patients to their baseline cognitive and functional status are important research priorities. up to 100% of icu survivors will suffer some degree of cognitive impairment at hospital discharge and approximately 50% will have decrements that persist for years. while the mechanisms for this newly acquired brain injury are poorly understood, several risk factors have been identified. unfortunately, it is unclear how to accurately predict long-term cognitive impairment. immediate opportunities to improve cognitive outcomes through risk reduction exist. the investigators propose to comprehensively study the prevalence of sleep abnormalities and their association with cognitive impairment, as it may yield potential targets for effective therapy. moreover, the investigators will examine for gene x environment associations \[apoe ε4\] that may allow for genetic risk stratification of individuals at greatest risk of cognitive impairment. the investigators hypothesize that eeg \[a sensitive longitudinal marker of brain dysfunction\] is a novel and independent predictor of long-term cognitive impairment, and possibly a candidate intermediate end point for future clinical trials. this study has the potential to identify novel biomarkers and risk factors for post-critical illness cognitive impairment, and may lay the foundation for rational interventions to mitigate risk in high-risk individuals.


Eligibility criteria:
inclusion criteria: * ≥16 years of age * admission to study icu for invasive mechanical ventilation \[minimum of 72 hours\] exclusion criteria: * advanced cognitive impairment or unable to follow simple commands before their acute illness \[e.g. end-stage alzheimer's disease\] * primary neurological injury \[e.g. anoxic brain injury, stroke or traumatic brain injury\] * anticipated death within 3 months of discharge \[e.g. palliative\] * uncontrolled psychiatric illness at hospital admission * not fluent in english * unlikely to adhere with follow-up \[e.g. no fixed address\] * residence greater than 300 kms from referral centre
treatment of myocardial infarction with bone marrow derived stem cells

Conditions: Acute Myocardial Infarction

Summary: the aim of the study is to investigate whether infusion of autologous bone marrow derived stem cells can improve cardiac function in the aftermath of a myocardial infarction.

primary coronary intervention within a few hours of a myocardial infarction has greatly reduced mortality as well as the risk of developing chronic heart failure. there are though still a large number of patients that develop symptoms of heart failure in the form of fatigue and breathlessness with physical exertion in spite of medical treatment. with the advance in stem cell technology there is now hope for the possibility of regenerating/repairing dead myocardial tissue, hence improving cardiac function. the current study is a pilot study that is going to precede a later double blinded randomized study. the aim of the study is to evaluate patient safety, optimize procedures, and to be used in power calculation in the design of the following study.

Eligibility criteria:
inclusion criteria: * chestpain * troponin t, \> 0,1ng/ml * succesfull revascularization of culprit lesion with pci. * no more than stenosis of 2 major epicardiel coronary arteries. exclusion criteria: * cardiogenic shock * known lvef\<45% * cardiomyopathy * atrialfibrillation or fluctuation * takyarytmia * infection * chronic inflammatory disease

Keywords: "stem cell" "autologous bone marrow transplantation" "myocardial infarction"
ambulatory blood pressure monitoring in rivaroxaban therapy

Conditions: Hypotension

Summary: one in ten patients on rivaroxaban therapy have dizziness and reductions in blood pressure. the investigators intend to monitor the ambulatory blood pressure of such patients in order to assess whether this is a true haemodynamic effect.


Eligibility criteria:
inclusion criteria: * aged 18-75 years * able to provide written, informed consent * taking rivaroxaban for any indication within the license of the drug, both once daily and twice daily dosing can be included * have measurable rivaroxaban levels on at least one occasion (this will be in line with standard of care, there will be no extra blood samples for the study) * not taking concomitant medication that can affect rivaroxaban metabolism (including amiodarone, dronedarone, -azole antifungals, protease inhibitors) * on no antihypertensive or vasoactive medication * have a baseline bp recording taken in clinic exclusion criteria: * unable to provide written, informed consent * presence of concomitant medication that may alter rivaroxaban levels and confound results (see above) * unwilling to undergo ambulatory blood pressure monitoring * contraindication to ambulatory blood pressure monitoring
evaluation of duloxetine and innovative pelvic floor muscle training in women with stress urinary incontinence

Conditions: Stress Urinary Incontinence in Women

Summary: this study will evaluate the safety, tolerability and efficacy of duloxetine and pelvic floor muscle training in women who suffer from stress urinary incontinence

this is a randomized-intervention, parallel, multicentric study which will evaluate the safety, tolerability and efficacy of oral duloxetine and innovative pelvic floor muscle training to woman suffering from stress urinary incontinence

Eligibility criteria:
inclusion criteria: * woman's willing to provide written informed consent * women over 18 years that experience uncomplicated stress urinary incontinence * score of the international consultation on urinary incontinence questionnaire ≥ 14 points * symptoms of urinary incontinence for at least 3 consecutive months * have at least seven urinary incontinence episodes per week * degree of pelvic organ prolapse ≤ 2 stage * willingness to accept the randomization process and fully participate in tests exclusion criteria: * recent use of any pharmacologic agent used to treat symptoms of urinary incontinence in the past six months * history of anti-incontinence surgery in the past 12 months * use of onabotulinumtoxina for the treatment of urinary incontinence in the past 12 months * history of pelvic prolapse repair or urethral surgery in the past 12 months * history of pelvic floor muscle training in the past 12 months * history of interstitial cystitis or bladder-related pain * chronic severe constipation * clinically significant renal or hepatic impairment * clinically significant heart impairment * pregnant woman, lactating, or actively trying to become pregnant * non-compliance with limitation of duloxetine treatment for mixed urinary incontinence * positive urinary tract infection * use of rehabilitation aids (pessary, urethral plugs, vaginal beads, etc.) * use of antidepressant therapy * insufficient understanding of pelvic floor exercises and/or omitting exercises * participation in any clinical study in the past six months

Keywords: stress urinary incontinence pelvic floor muscle training
efficacy and safety of spd417 in treatment of manic symptoms in adults with bipolar i disorder

Conditions: Bipolar Disorder

Summary: the purpose of this study is to compare the efficacy and safety of spd417 in treating bipolar manic symptoms, when given once daily in the evening vs. twice daily.


Eligibility criteria:
inclusion criteria: * dsm-iv criteria for bipolar i disorder * screen ymrs score =\> 16 * women of childbearing potential agree to take adequate precautions against contraception exclusion criteria: * hospitalization required for treatment of psychiatric symptoms * patients who meet dsm-iv for ultra-rapid cycling * history of serious suicide attempt requiring medical intervention
efficacy study of pentosan polysulfate sodium,hydrodistension and combination therapy for bladder pain syndrome

Conditions: Bladder Pain Syndrome; Pentosan Polysulfate; Hydrodistension

Summary: the efficacy of pentosan polysulfate sodium, hydrodistension and combination therapy in patients with bladder pain syndrome.


Eligibility criteria:
inclusion criteria: 1. men and women who were over 18 years old and had symptoms over 6 months. 2. 4 or more with an pain visual analogue score 3. 12 or more o'leary-sant intersttial cystitis questionnaire (ic-q) symptom and problem score and with a pain score and nocturia score of 2 or more. exclusion criteria: 1. history of hydrodistention,augumentation cystoplasty due to ic/bps 2. pentosan polysulfate sodium (elmiron) history over 1 month within 6 months. 3. women of child-bearing potential who were pregnant or nursing 4. mean voided volume lesser than 40ml or over than 400ml. 5. hematuria exceeds 1+ in the urinary dipstick (dipstick) examination. 6. urinary tract infection during run-in periods. 7. genitourinary tuberculosis or bladder,urethral and prostate cancer 8. recurrent urinary tract infection 9. history of hystrectomy,mid-urethral sling,pelvic organ prolapse repair,vaginal delivery or cesarean section,prostate opreation or treatment etc within 6months. 10. neurologic disease history of cerebral infaction,multiple sclerosis or parkinsonism etc.

Keywords: bladder pain syndrome pentosan polysulfate hydrodistension
effectiveness of egg versus whey protein powder during resistance training

Conditions: Muscle Atrophy

Summary: consumption of whole eggs has recently been shown to stimulate muscle protein synthesis to a greater degree than consumption of egg whites after a resistance training session. it is theorized that the egg yoke contains bio-active nutrients that enhance the protein provided by egg whites. the study will evaluate the effect of whole egg powder compared to whey protein powder and placebo over 12 weeks of resistance training in men and women who are participating in resistance training programs.

consuming whole eggs after resistance training sessions appears to be more effective for simulating muscle protein synthesis that simply consuming egg whites. the egg yolks might enhance the effect of protein derived from egg whites. the study will compare post-exercise supplementation with about 30 grams of protein derived from whole egg powder versus whey protein powder and placebo (maltodextrin) over a 12-week resistance training program. resistance-trained men and women (n=120) will be randomized to consume either the whole-egg powder, whey protein powder or maltodextrin after resistance training 6 times per week for 12 weeks. the primary outcome measure is change in lean tissue mass. secondary measures include change in fat mass, change in arm and leg muscle thickness, change in bench press, squat, and knee extension strength, and change in fasting blood glucose.

Eligibility criteria:
inclusion criteria: * resistance training experience for at least one year exclusion criteria: * having taken any nutritional supplements the past 30 days * currently using anabolic steroids * currently taking corticosteroids * allergies to dairy or egg products * identifying any medical conditions as determined by the "get active questionnaire"
assessment of the efficacy and safety of oroxid® oral solution in patients with oral cavity surgery

Conditions: Tooth Extrusion; Wound Healing

Summary: oral tissue healing is significantly affected by the high bacterial load and constant mechanical stress within the oral cavity. to control bacterial colonization and support healing, both topical and systemic treatments-such as antibiotics and anti-inflammatory agents-are commonly recommended. in addition to pharmacological therapies, mouthwashes containing peroxide, hyaluronic acid, chitosan, or chlorhexidine are often used to maintain low levels of pathogenic bacteria. however, current recommendations for mouthwash use are primarily based on their antibacterial properties in a healthy oral environment. evidence supporting their role in promoting wound healing, particularly after oral surgery, remains limited. oroxid® mouthwash is a medical device formulated with active oxygen (peroxide compounds). it supports the prevention and relief of inflammation in gingival and paranasal tissues through mechanical action: the release of oxygen bubbles helps cleanse tissues by removing debris. oroxid® acts locally on the mucosal microenvironment by moistening, oxygenating, and clearing away particles and dead cells. additionally, its slightly acidic ph (between 3 and 5) helps inhibit microbial growth. the investigators hypothesize that oroxid® may reduce post-operative side effects and complications following wisdom tooth extraction and contribute to faster wound healing.


Eligibility criteria:
inclusion criteria: 1. systemically healthy individuals aged 18 years or older. 2. indicated for surgical removal of an erupted or unerupted tooth and/or apicoectomy. 3. ability and willingness to comply with post-operative oral hygiene instructions. 4. signed informed consent form prior to participation in the study. exclusion criteria: 1. receipt of periodontal treatment within the past 3 months. 2. use of mouthwashes or oral gels in the past month. 3. presence of active gingivitis around the tooth scheduled for extraction. 4. known allergy to any ingredients of the investigational products. 5. presence of inflammatory conditions in the oral cavity, such as lichen planus, bullous lesions, or active gingivitis. 6. immunocompromised individuals. 7. known allergy to penicillin or diclofenac. 8. pregnant or breastfeeding women. 9. smokers who consume more than 15 cigarettes per day.

Keywords: oral cavity wound hydrogen peroxide mouthwash
determinants of olfactory dysfunction in chronic rhinosinusitis

Conditions: Chronic Rhinosinusitis; Olfactory Dysfunction

Summary: olfactory dysfunction is a cardinal symptom of chronic rhinosinusitis, a disease which affects 12.5% of the adult population across all racial and ethnic groups. previous research has documented olfactory deficit in 68% of patients with chronic rhinosinusitis and 20% with complete anosmia, suggesting that olfactory dysfunction affects over 25 million individuals in the united states with chronic rhinosinusitis. this proposed investigation will be used to predict olfactory outcomes following treatments for chronic rhinosinusitis and gain insights into mechanisms of olfactory dysfunction in this population.


Eligibility criteria:
inclusion criteria: * adult ( \> 18 years of age) * a diagnosis of medical recalcitrant crs as defined by 2015 adult sinusitis guidelines outlined by the american academy of otolaryngology * provide written informed consent and authorization. * study participants must be able to complete consent, all study evaluations, olfactory testing, and study-related health questionnaires written in the english language. * patients must self-select subsequent treatment option (endoscopic sinus surgery or continued medical therapy) to be dictated by the disease process and judgment and preferences of each individual, following counseling for each treatment option. * present to the enrolling site with indication for a ct scan or a ct scan completed, off-site, from another provider * complete appropriate standardized medical treatment by the interim assessment, 6-week follow-up period including, but not limited to, at least one course of either topical corticosteroids (\>21-days) or a 5-day course of oral corticosteroid therapy, and at least one course (\>14-days) of culture-directed or broad spectrum antibiotic therapy. exclusion criteria: * children (\< 18 years of age) * any patient unable and/or unwilling to complete questionnaires or clinical testing or cooperate with all study protocols. * non-english speaking / english translation services required * unwilling or unable to provide informed, written consent. * contra-indications for any type of continued medical therapy required for treatment of symptoms related to crs * patients who have not undergone previous prescribed medical therapy as described in inclusion criteria. * individuals of any vulnerable population including: children, pregnant women, neonates, decisionally impaired adults, or prisoners.
comparison of static stretching and deep kneading massage among plantar fasciitis patients

Conditions: Plantar Fasciitis

Summary: comparison of static stretching and deep kneading massage among plantar fasciitis patients

to find out the better type of intevention in static stretching and deep kneading massage for the betterment of plantar fasciitis patients

Eligibility criteria:
inclusion criteria: * a person with phytoplitis by a doctor, physiotherapist or orthopedic surgeon. * determine the patient's age between 40 and 60 years. * the patient's fracture, fracture, most cancers and various metabolism disorders are not used. male and female victims can be involved. exclusion criteria: * inflammatory arthritis patients. * nerve distortions * another disease caused in the case of march. * patients with various basic muscle problems and the effects of red science * does not use the patient's latest records and footprint.
the prevention of postmenopausal osteoporosis with lasofoxifene and cytokine evaluation

Conditions: Bone Loss

Summary: the objective of the study is to demonstrate the effects that lasofoxifene has on serum markers of bone metabolism.


Eligibility criteria:
inclusion criteria: * postmenopausal women over 50 years who have low bone mineral density. exclusion criteria: * women who are under 50 years of age, are premenopausal, or who currently have osteoporosis are excluded.

Keywords: osteoporosis lasofoxifene bone density bone markers
immunological response after ablative therapy in the liver

Conditions: Hepatocellular Carcinoma; Immune Response

Summary: local ablative treatment of hepatocellular carcinoma is performed primary on patients not eligible for liver transplant or liver resection. at our hospital two different methods are used: microwave ablation, where the tumor cells are heated up and killed, and irreversible electroporation, where the tumor cells are exposed to an electrical field and nano-pores are formed in the cell membranes and the cells go into apoptosis (programed cell death). previous studies have shown effects on the immune system after ablative therapies. the purpose of this study is to compare the immunological response after the wo different methods of killing the tumor cells.


Eligibility criteria:
inclusion criteria: * hepatocellular carcinoma, maximum 3 lesions, maximum 30 mm in any cross section diameter * physically fit to undergo general anaesthesia * fully understand swedish instructions regarding the study exclusion criteria: * atrial fibrillation (for irreversible electroporation) * pacemaker (for irreversible electroporation) * \>3 lesions * \> 30 mm in any cross section diameter

Keywords: irreversible electroporation microwave ablation